• SENSEX
    NIFTY 50
Market

CNBC-TV18's top stocks to watch out for on June 22

Updated : 2020-06-22 07:20:27

The Indian market is likely to open lower on Monday tracking weakness in Asian peers as the number of coronavirus cases stateside soared again. At 7:00 am, the SGX Nifty was trading 37 points lower at 10,200.00, indicating a negative start for the Sensex and Nifty50.

 Housing Development Finance Corporation (HDFC) : The mortgage lender said that its committee of directors has approved raising up to Rs 14,000 crore via qualified institutions placement (QIP) or any other mode in one or more tranches.
Housing Development Finance Corporation (HDFC): The mortgage lender said that its committee of directors has approved raising up to Rs 14,000 crore via qualified institutions placement (QIP) or any other mode in one or more tranches.
 HDFC Bank:  The bank’s board has approved a proposal to raise up to Rs 50,000 crore by issuing various debt securities in the next twelve months.
HDFC Bank: The bank’s board has approved a proposal to raise up to Rs 50,000 crore by issuing various debt securities in the next twelve months.
 Punjab National Bank:  The bank’s net loss narrowed to Rs 697.20 crore in Q4FY20 from Rs 4,750 crore, YoY. Provisions for bad loans fell 51.33 percent YoY to Rs 4,901.31 crore.
Punjab National Bank: The bank’s net loss narrowed to Rs 697.20 crore in Q4FY20 from Rs 4,750 crore, YoY. Provisions for bad loans fell 51.33 percent YoY to Rs 4,901.31 crore.
 Glenmark Pharmaceuticals:  Indian drug regulator has approved Favipiravir for the treatment of mild to moderate COVID-19 in India. Glenmark’s Fabiflu is the first oral Favipiravir-approved medication for the treatment of COVID-19 and has been launched in few centers. Fabiflu, available as a 200 mg tablet, has been priced at Rs 103 per tablet.
Glenmark Pharmaceuticals: Indian drug regulator has approved Favipiravir for the treatment of mild to moderate COVID-19 in India. Glenmark’s Fabiflu is the first oral Favipiravir-approved medication for the treatment of COVID-19 and has been launched in few centers. Fabiflu, available as a 200 mg tablet, has been priced at Rs 103 per tablet.
 Cipla:  The company has launched remdesivir under the brand name Cipremi and will be marketing and supplying the drug through both government and open market channels. The drug has been approved for adult and pediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection, particularly those on oxygen support.
Cipla: The company has launched remdesivir under the brand name Cipremi and will be marketing and supplying the drug through both government and open market channels. The drug has been approved for adult and pediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection, particularly those on oxygen support.
 ONGC:  The company has said that the COVID-19 pandemic will impact the speed of execution of its projects. Gas output was down by 9 percent on account of less demand and offtake by customers due to the lockdown. Lower oil and gas prices are expected to impact the internal resource generation capacity of the company, it said. (Image: Reuters)
ONGC: The company has said that the COVID-19 pandemic will impact the speed of execution of its projects. Gas output was down by 9 percent on account of less demand and offtake by customers due to the lockdown. Lower oil and gas prices are expected to impact the internal resource generation capacity of the company, it said. (Image: Reuters)
 Piramal Enterprises:  The company has entered into an agreement with G&W Laboratories Inc. to acquire its solid oral dosage drug product manufacturing facility in Pennsylvania for $17.5 million.
Piramal Enterprises: The company has entered into an agreement with G&W Laboratories Inc. to acquire its solid oral dosage drug product manufacturing facility in Pennsylvania for $17.5 million.
 LIC Housing Finance:  The company reported a 39 percent fall in Q4FY20 net profit to Rs 424.31 crore from Rs 696.91 crore while net interest income fell 8.2 percent to Rs 1,155 crore.
LIC Housing Finance: The company reported a 39 percent fall in Q4FY20 net profit to Rs 424.31 crore from Rs 696.91 crore while net interest income fell 8.2 percent to Rs 1,155 crore.
 Cadila Healthcare:  The company reported a 14.82 percent decline in Q4FY20 net profit to Rs 391.90 crore versus Rs 460.1 while revenue from operations stood at Rs 3,752.1, YoY.
Cadila Healthcare: The company reported a 14.82 percent decline in Q4FY20 net profit to Rs 391.90 crore versus Rs 460.1 while revenue from operations stood at Rs 3,752.1, YoY.
 Ramco Systems:  The company reported a net loss of Rs 5.85 crore in Q4FY20 versus profit of Rs 8.7 crore and revenue was at Rs 132.87 crore versus Rs 141.44 crore, YoY.
Ramco Systems: The company reported a net loss of Rs 5.85 crore in Q4FY20 versus profit of Rs 8.7 crore and revenue was at Rs 132.87 crore versus Rs 141.44 crore, YoY.
 Dalmia Bharat Sugar:  The company reported Q4FY20 profit at Rs 61.95 crore versus Rs 43.3 crore and revenue at Rs 550 crore versus Rs 568.94 crore, YoY.
Dalmia Bharat Sugar: The company reported Q4FY20 profit at Rs 61.95 crore versus Rs 43.3 crore and revenue at Rs 550 crore versus Rs 568.94 crore, YoY.
Live TV

recommended for you

Ask Our Experts CNBC TV18

Advertisement